Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
Cells in the outermost layer of the heart can be guided by a specific protein to move deeper inside and help to repair a failing adult heart. Research published today by Nature, reveals how thymosin ?4, a protein already known for its ability to reduce muscle cell loss after heart attack, can instruct the heart to heal itself.
GE (NYSE: GE) and Hitachi, Ltd. (NYSE: HIT) (TSE: 6501) have signed a letter of intent to negotiate the formation of a global alliance that will combine their new nuclear power plant and services businesses with the goal of strengthening their existing operations, accelerating the development of new products and services, and positioning their alliance for growth in the nuclear energy industry.
For decades, researchers have suspected a connection between chronic lung diseases and rheumatoid arthritis (RA). Previous research has yielded widely varying estimates about the strength of this connection, partly because studies have used different diagnosis criteria for these diseases.
UCLA researchers in collaboration with researchers at Rutgers University have solved longstanding mysteries surrounding DNA transcription, the first step in carrying out instructions contained in our genes.
A new method of treating mitral regurgitation (MR), the leaking of blood through the mitral valve into the heart chamber, provides a less-invasive alternative to open heart surgery. A study published in Journal of Interventional Cardiology found that a variety of advances have allowed for the potential treatment of MR through various catheter techniques, similar to angioplasty. While over 50,000 mitral valve surgical procedures are performed annually, open surgery is an undesirable option, especially for high-risk patients.
Cardinal Health, Inc., the leading provider of products and services supporting the health-care industry, today announced the results from the first end-to-end test of a technology that could further improve the safety and efficiency of the nation?s pharmaceutical supply chain.
Wal-Mart Stores, Inc., (NYSE: WMT) announced that starting today, it is rolling out its $4 generic prescription program in 11 additional states and adding 17 more prescriptions to the program. With the announcement, the expanded $4 generic prescription program will now be available in an additional 502 stores throughout Idaho, Kentucky, Maine, Massachusetts, Nebraska, Oklahoma, Rhode Island, South Carolina, Utah, Washington and West Virginia.
Wal-Mart Stores, Inc., (NYSE: WMT) announced that starting today, it is rolling out its $4 generic prescription program in 11 additional states and adding 17 more prescriptions to the program. With the announcement, the expanded $4 generic prescription program will now be available in an additional 502 stores throughout Idaho, Kentucky, Maine, Massachusetts, Nebraska, Oklahoma, Rhode Island, South Carolina, Utah, Washington and West Virginia.
A survey of over 700 UK family doctor practices has shown that two-thirds provide PSA testing for prostate cancer on demand, despite lack of evidence that this approach is effective. This represents a major pressure on family doctors and cancer services alike, says the paper in BJU International.